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Background and Purpose: Since publication of previous meta-analyses comparing endovascular and surgical treatment of
patients with carotid artery stenosis, two further large-scale trials have been conducted, almost doubling the number of
patients available for analysis. Therefore, it is justified to update these meta-analyses.
Methods: Relevant trials were identified by a search of the literature using an electronic database. Trials with a
nonrandomized patient allocation were not included. We focused on events within 30 days after intervention and made
two sets of analysis: one with all trials and one with large trials exclusively including symptomatic patients.
Results: Only Endartérectomie Versus Angioplastie chez les patients ayant une Sténose carotide Symptomatique Serrée
(EVA3S) and Stent-Supported Percutaneous Angioplasty of the Carotid Artery versus Endarterectomy (SPACE) were
identified to be included in the updated meta-analysis. In total, 2985 patients were included in eight trials of which 89%
were symptomatic. In contrast to previous analyses, this meta-analysis found a significant difference between the odds
ratios of any stroke or death within 30 days after treatment with a disadvantage of endovascular treatment when analysing
all trials (odds ratio [OR], 1.38; 95% confidence interval [CI] 1.04-1.83; P  .024). Significant heterogeneity was found
for this analysis (P  .03). The increase of the odds of suffering from disabling stroke or death in the endovascular
compared with the surgical group was not significant in the analysis of all trials (OR, 1.37; 95% CI, 0.92-2.04; P  .12);
no heterogeneity was found for this analysis (P  .27). In the analysis of the large trials with symptomatic patients, the
OR for the endpoint any stroke or death was 1.29 (95% CI 0.94-1.76; P  .11); with a hint for heterogeneity (P  .10).
For the endpoint disabling stroke or death, the OR was 1.33 (95% CI 0.89-1.93; P .17) without any heterogeneity
(P  .58).
Conclusion: The expressiveness of this meta-analysis is limited by the heterogeneity of some tests. The main result is that
surgical treatment still remains the gold standard for treatment of patients with symptomatic carotid artery stenosis, who
do not have an increased surgical risk. Carotid artery stenting is neither safer than nor as safe as carotid endarterectomy
in large clinical trials when short-term stroke and death rates are taken into account. Further recruitment into ongoing
randomized trials is strongly recommended. ( J Vasc Surg 2008;47:350-5.)Safety and efficacy of endovascular treatment in com-
parison with carotid endarterectomy in patients with either
symptomatic or asymptomatic severe carotid artery stenosis
is still a matter of ongoing debate. Two meta-analyses on
this subject were published in 2005, analyzing six random-
ized trials.1,2 In the meantime, two more large-scale trials
exclusively including patients with symptomatic carotid
artery stenosis have been published, almost doubling the
number of patients available for analysis.3,4 Therefore, we
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350thought it would be important to update the recently
published meta-analyses, focusing in particular on patients
with symptomatic stenosis. Because limited long-term
follow-up data of these two trials are available or have been
published with respect to the older trials, we limited the
present meta-analysis to safety concerns.
MATERIAL AND METHODS
Relevant trials were identified by a search of the litera-
ture using an electronic database (PubMed). Search terms
included the phrases carotid arteries, stenosis, endovascu-
lar, stenting, angioplasty, endarterectomy, and randomized
in various combinations. The search was limited to publi-
cations between October 2004 and March 2007. Random-
ized trials comparing carotid endovascular treatment with
carotid endarterectomy in patients of any age or sex with
carotid artery stenosis were included. Trials with a nonran-
domized patient allocation were excluded.
For each study, data were sifted out regarding random-
ization, number of patients allocated to each treatment
modality, and the outcome following an intention-to-treat
principle, number of patients treated within the allocated
treatment arm, intervention characteristics, and outcome
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days after procedure. Strokes were classified, if possible, as
disabling or not, based on the method used by the authors
of the original publication. Data from earlier trials (prior to
October 2004) were extracted from the previous meta-
analyses and verified using the original publication by two
of the authors (PR, HHE). The analysis was restricted to
30-day events because we were aware that only few relevant
long-term data have been published. In addition, no anal-
yses of cardiovascular events or local complications (eg,
nerve palsy) have been done because these have not been
reported from the Stent-Supported Percutaneous Angio-
plasty of the Carotid Artery versus Endarterectomy (SPACE)
trial so far.
Two sets of trials were used for a meta-analysis. First, all
identified trials were combined to be consistent with previ-
ous publications. Second, only trials with more than 200
patients, at least nearly exclusive inclusion (95%) of pa-
tients with symptomatic stenosis and peer-reviewed publi-
cation were combined.
Results of the meta-analysis were reported as odds
ratios (OR), (the odds of an unfavorable outcome among
patients treated by endovascular intervention compared
with the corresponding odds among patients treated surgi-
cally) and were calculated using the Peto fixed-effect
method. This method was used to be consistent with the
previous published meta-analyses. Heterogeneity was as-
sessed using Cochran Q statistic, and P values obtained by
comparing the statistic with a 2 distribution with k-1
degrees of freedom, where k is the number of studies. We
also used the I2 statistic, which describes the percentage of
variation across studies that is due to heterogeneity rather
than chance and is calculated as 100% x (Q-df)/Q where Q
is the Cochran Q statistic.5 I2 is an intuitive and simple
expression of the inconsistency of studies’ results because,
unlike Q, it does not inherently depend upon the number
of studies considered. For all analyses StatsDirect statistical
software version 2.5.6 was used.
RESULTS
In addition to the trials analyzed by Coward and Qureshi
(Leicester,6 WALLSTENT,7 CAVATAS,8 Kentucky-A9 and
–B,10 SAPPHIRE11) only EVA3S and SPACE fulfilled our
criteria and were included in the updated meta-analysis. An-
other large-scale trial (CaRESS) was excluded because of the
nonrandomized treatment allocation.12 Another small trial
included i n t h e meta-analysis of Qureshi2 was not included
in our study because the published results were incomplete.
Twenty-three patients were randomized into this trial,
30-day follow-up data of only 13 of these patients were
reported.13 In total, 2985 patients were enrolled in these
eight trials of which 2646 (89%) were symptomatic. Five of
the eight trials included only patients with symptomatic
carotid artery stenosis, one of them is not peer reviewed
published,7 and two of them were small.9,10 The majority
(71%) of the SAPPHIRE-population were asymptomatic
patients. Baseline data or results for the subgroup of symp-
tomatic patients could not be extracted from the originalpublication or subsequent publications.11 Therefore, this
trial was not included in the second meta-analysis. In
contrast, CAVATAS was included into the second analysis
because only 16 (3.2%) of the patients were asymptomatic.
In total, only three trials remained for the second meta-
analysis.
A summary of the trials published before 2005 is not
presented here; this can be found in the work of Coward
et al.1
EVA3S. The Endartérectomie Versus Angioplastie
chez les patients ayant une Sténose carotide Symptoma-
tique Serrée (EVA3S) was a French multicenter, noninferi-
ority randomized trial with national research organization
funding.4 Patients were eligible if they had experienced a
carotid transient ischemic attack (TIA) or nondisabling
stroke within 4 months before randomization, associated
with an atherosclerotic stenosis within the ipsilateral carotid
bifurcation of at least 60%NASCET, which investigators be-
lieve was suitable for both carotid surgery and angioplasty.
The primary endpoint was any stroke or death within 30
days of the procedure. In EVA3S, the interventionalists had
to document at least 12 cases of carotid artery stenting
(CAS) or at least five cases of CAS and 30 cases of endo-
vascular treatment of other supra-aortic trunks.14 Since
February 2003, the use of a emboli protection device
(EPD) was mandatory. A total of 92% of the EVA3S-CAS-
patients were treated with an EPD.15 In September 2005,
recruitment into EVA-3S was stopped by the data safety
and monitoring board after enrolling 527 patients. A total
of 265 patients were randomized into the CAS and 262
into the CEA group. Seven patients, who did not undergo
carotid repair, were excluded from the intention to treat
(ITT) analysis of the risk of any stroke or death within 30
days after treatment. Primary outcome events occurred in
25 (9.6%) patients of the CAS and in 10 (3.9%) of the CEA
group. This reflects an odds ratio of 2.5 (95% confidence
interval [CI] 1.2-5.1; P  .01) for an increased periproce-
dural risk in the CAS group. Disabling strokes or death
occurred in nine (3.4%) patients of the CAS and four (1.5%)
patients of the CEA group.
SPACE. The Stent-Supported Percutaneous Angio-
plasty of the Carotid Artery versus Endarterectomy (SPACE)
trial investigated whether CAS is not inferior to CEA in the
treatment of severe symptomatic carotid artery stenosis.3
The trial was done in Germany, Austria, and Switzerland.
Patients over the age of 50 years with symptomatic (tran-
sient ischemic attack or minor stroke) stenosis (at least
70%ECST) eligible for both methods could be recruited into
this trial. Primary endpoint of SPACE was the rate of
ipsilateral stroke or death between randomization and day
30 after treatment. The 30-day rate of any stroke or death
was not a prespecified endpoint, but can easily calculate
from other endpoint data. In SPACE, the primary interven-
tionalist of each center had to demonstrate 25 successful
interventions prior to participation in the trial, whereas
secondary investigators got a preliminary certificate after 10
interventions. A second interim analysis based on 1200
patients revealed primary event rates of 6.84% in the CAS
rectom
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calculation found that 2500 patients would be necessary to
proof the noninferiority of CAS with a power of 80%.3
Therefore, randomization was stopped after 1214 patients.
In this entire population, the rate of ipsilateral stroke or
death was 6.92% in the 607 patients of the CAS and 6.45%
in the 589 patients of the CEA group. The upper limit of
the 95% confidence interval (CI) of the absolute risk reduc-
tion was 2.87 and, thus, exceeded the predefined noninfe-
riority margin of 2.5%. Therefore, SPACE failed to prove
the noninferiority of CAS compared with CEA in treating
patients with symptomatic carotid artery stenosis. The rate
of any stroke or death within 30 days was 7.4% in the CAS
and 6.6% in the CEA group. The rate of disabling stroke or
death was 5.1% in the CAS and 3.9% in the CEA group. In
SPACE, the use of an EPD was left to the discretion of an
investigator; finally, 27% of the SPACE-CAS population
was treated with an EPD.
The eight trials differ significantly regarding the study
population and technical details. SAPPHIRE attempted to
include only patients considered to be at high surgical risk for
CEA. In three trials, diagnostic angiography was mandatory
before randomization and therefore, its risk added to the
treatment. In the other five trials, patients could be random-
ized according to the results of noninvasive techniques, mainly
duplex ultrasound. In CAVATAS, the majority of the patients
were treated by angioplasty alone: only 26% were treated using
a stent. Use of an EPD was mandatory in SAPPHIRE and in
a predominant number of patients in EVA3S. In SPACE, it
was left to the investigators’ discretion whether to use an
EPD. Slight differences were also present in terms of stroke
definition: SPACE and EVA3S counted all events lasting
longer than 24 hours, whereas some other trials used a 7-day
time interval. The outcome as a composite of any stroke or
death within 30 days after procedure was available for all eight
trials. Data on disabling strokes were available for six trials.
Disability was defined as a score of at least 3 on the modified
Rankin Scale (mRS) in EVA3S and SPACE. CAVATAS de-
fined disability as requiring help from another person for more
than 30 days, which is roughly equivalent to a score of 3 or
above on the mRS. The table shows the rates of outcome
Table. Rates of outcome events at 30 days from the rando
in patients with severe carotid artery stenosis (ITT data)
30-day stroke or death
Outcome CAS - no (%) CEA
Leicester6 5 (45.5) 0
WALLSTENT7 13 (12.1) 5
CAVATAS8 25 (10.0) 25
Kentucky-A9 0 (0) 1
Kentucky-B10 0 (0) 0
SAPPHIRE11 8 (4.8) 9
EVA3S4 25 (9.6) 10
SPACE 45 (7.4) 39
ITT, Intention to treat; CAS, carotid artery stenting; CEA, carotid endarteevents for each of the studies.Meta-analysis of all studies shows a significant 38% in-
crease in the odds of suffering any stroke or death within 30
days after treatment in the endovascular treatment group
compared with the surgical group (OR, 1.38; 95% CI 1.04-
1.83; P  .024). A significant heterogeneity was found
(Cochran Q  14.0; P  .03) with an I2 of 57.1% (Fig 1, a).
After exclusion of non-peer-reviewed and small trials and
those with a majority of asymptomatic patients, the combined
OR is somewhat smaller (1.29) and the 1 is included within
the 95% confidence interval (95% CI 0.94-1.76; P  .11). No
significant heterogeneity was found for this analysis (Cochran
Q  4.5; P  .10). However, an I2 value of 55.9% is still
regarded as substantial heterogeneity (Fig 2, a).16
Combining all trials, there was a nonsignificant 37% in-
crease of the odds of suffering disabling stroke or death after
treatment in the endovascular treatment group compared
with the surgical group (OR, 1.37; 95% CI, 0.92-2.04;
P  .12). No significant heterogeneity was found for this
analysis (Cochran Q 5.2; P .27) with a substantially low
value of I2 (22.8%) (Fig 1, b). In the analysis of the large trials
with symptomatic patients, we obtained a combined OR very
close to the previous one (1.33; 95% CI 0.89-1.93; P .17);
no significant heterogeneity was found (Cochran Q  1.1;
P  .58) with an I2 value of 0% (Fig 2, b).
DISCUSSION
It has long been established that carotid endarterectomy
can prevent further strokes after a cerebrovascular event has
been caused by severe carotid artery stenosis. A combined
analysis of the data from three major randomized trials found
a 30-day rate of any stroke or death of 8.4% in patients with
moderate (50%-69%NASCET) and of 6.2% in patients with
severe (70%-99%NASCET) carotid artery stenosis.17 Carotid
artery stenting has been increasingly used for treatment of
patients with carotid artery stenosis, despite the lack of evi-
dence from large-scale randomized trials of equivalent
periprocedural risk and efficacy. Two major trials have been
published in 2006.3,4 One found no significant differences
with regard to periprocedural risk between the two treatment
modalities, but missed the primary aim of proving that CAS
was not inferior.3 The other trial found a significantly in-
d trials comparing endovascular with surgical treatment
30-day disabling stroke or death
(%) CAS - no (%) CEA - no (%)
3 (27.3) 0 (0)
) unknown unknown
) 16 (6.4) 15 (5.9)
) 0 (0) 1 (2.2)
0 (0) 0 (0)
) unknown unknown
) 9 (3.4) 4 (1.5)










(6.6creased risk for CAS.4
ithin
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number was doubled compared with the previous ones. In
addition, we were able to include the entire SPACE-cohort
in this analysis and not only the cohort of the second interim
analysis, which has been published so far. After inclusion of
these two trials in themeta-analysis of all available randomized
trials, a significantly increased periprocedural risk for the en-
dovascular treatment regarding any stroke or death compared
with the surgical treatment can be demonstrated. But for this
endpoint, significant heterogeneity was found between the
trials, limiting the expressiveness of this analysis. A meta-
analysis using a randommodel, revealed a nonsignificant trend
towards surgery (OR 1.46; 95% CI 0.9-2.35). Therefore, this
result has to be interpreted with caution.
Possible reasons for the heterogeneity are the facts that
Fig 1. Effect of endovascular vs surgical treatment for p
trials on the combined endpoint (a) any stroke or death wsome trials also included asymptomatic patients, that the en-dovascular technique changed during the time, and that the
operator experience was different between the trials. These
differences were the main reason to perform also a meta-
analysis focused on the large trials with symptomatic patients.
Beside the two recent trials, we included only CAVATAS into
this analysis because the other trials did not report the results
of the symptomatic subgroup,11 were not peer-reviewed,7 or
included only few patients.9 This analysis found a nonsignifi-
cant difference in favor of the surgical therapy. We did not
focus on the analysis of different interventional techniques
and, therefore, added also CAVATAS into this analysis de-
spite different endovascular techniques; CAVATAS pre-
dominantly used balloon angioplasty alone, whereas the
later tended to use stenting with cerebral protection. Nev-
ertheless, no heterogeneity was found for this analysis.
s with severe carotid artery stenosis from all randomized
30 days and (b) disabling stroke or death within 30 days.atientAlso, the prerequisites for the investigators seemed to have
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For instance, in EVA3S, the periprocedural complication
rate was not different between experienced and inexperi-
enced physicians.18 This was also observed in the recently
published CAPTURE registry.19 This registry included
3500 patients with high surgical risk, comparable with the
SAPPHIRE criteria. All patients were examined within 14
days prior to treatment by an independent neurologist. The
neurologist examination was repeated at 24 hours and at 30
days after procedure. The overall complication rate, ex-
pressed as the rate of composite of death, any stroke, or
myocardial infarction within 30 days postprocedure was
6.3% It is remarkable that most patients were asymptomatic
(n 3018) with a complication rate of 5.4%; for symptom-
atic patients (n 482) the complication rate was 12.0%. In
SAPPHIRE, which was the rationale for this post approval
registry, this rate had been 2.1% in the symptomatic sub-
group.11 It should be mentioned that based on level Ia
evidence acceptable complication rates are 3.0% for asymptom-
atic and 6.0% for symptomatic patients.20,21 In CAPTURE,
three different levels of operator experiences were defined
with almost no statistical differences in outcomes by physi-
Fig 2. Effect of endovascular vs surgical treatment for
randomized, peer-reviewed published trials on the com
(b) disabling stroke or death within 30 days.cian levels in all patients or in the subgroups of asymptom-atic patients. In symptomatic patients, there was a trend
towards better results with higher level of experience (4.2%
vs 12.4%), but only 48 patients were treated by highly
experienced operators, therefore the confidence interval is
broad and this difference also is not significant.
Another argument for the less important influence of
the technique or the operator experience for the periproce-
dural risk are the comparable complication rates in the CAS
groups of these three trials: 10.0% in CAVATAS, 9.6% in
EVA3S, and 7.7% in SPACE for any stroke or death. Thus,
the differences between CAVATAS, EVA3S, and SPACE
can hardly be explained with differences in the endovascular
arms. It is more important that there were relevant differ-
ences within the surgical arms. Despite the long experience
of surgeons with carotid endarterectomy in any trial, almost
a threefold difference between the surgical complications
rates can be observed: 3.9%, 6.5%, and 9.9% in EVA3S,
SPACE, andCAVATAS, respectively. The reasons for these
differences are still under discussion.
Another reason for the heterogeneity between the trials
is the early data-dependent stop of EVA3S. Such “early
stopped trials” are at risk of over-estimating the risk or
ts with severe symptomatic carotid artery stenosis from
endpoint (a) any stroke or death within 30 days andpatien
binedbenefit of the treatment.
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death, there was no statistically significant difference between
the two treatment modalities in both analyses. However, the
power of the comparison was low with only 100 events in six
trials providing information about stroke severity. Neverthe-
less, the size of the effectwas comparable (one third increase in
relative risk) with that observed with the endpoint any stroke
or death, and no heterogeneity was observed.
CONCLUSIONS
Based on the significant heterogeneity of the overall
meta-analysis and the nonsignificant differences in the
other analyses, themain result of this analysis is that surgical
treatment is still the gold standard for treatment of patients
with symptomatic carotid artery stenosis, who do not have
an increased surgical risk.
According to present knowledge, CAS has not yet been
shown to be as safe as or even safer than carotid endarter-
ectomy in large clinical trials when considering short-term
stroke and death rates. To increase the knowledge about
the role of CAS in treating patients with carotid artery
stenosis, further recruitment into ongoing randomized tri-
als is strongly recommended.
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